Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

The dearth of antibiotic development  (AAC ed.)

The dearth of antibiotic development (AAC ed.)

FromEditors in Conversation


The dearth of antibiotic development (AAC ed.)

FromEditors in Conversation

ratings:
Length:
44 minutes
Released:
Sep 2, 2020
Format:
Podcast episode

Description

Why are we running out of antibiotics? A look at the pharmaceutical development of one of the most life-saving class of drugs. Topics discussed: The reasons behind the stagnant and declining antibiotic development pipeline New initiatives focused on stimulating the antibiotic market Strategies to spur the antibiotic development Guests: Helen Boucher, MD. Professor of Medicine and Chief, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Editor of AAC Karen Bush, PhD. Professor of Practice & Interim Director, Biotechnology Program Indiana University. Former Editor AAC. Visit aac.asm.org to read current and archived issues of the Antimicrobial Agents and Chemotherapy journal.
Released:
Sep 2, 2020
Format:
Podcast episode

Titles in the series (81)

Editors in Conversation is the official podcast of the American Society for Microbiology Journals. Editors in Conversation features discussions between ASM Journals Editors, researchers and clinicians working on the most cutting edge issues in the microbial sciences. Topics include laboratory diagnosis and clinical treatment of infectious diseases, antimicrobial resistance, epidemiology of infections, multidrug-resistant organisms, pharmacology of antimicrobial agents, susceptibility testing, and more. The podcast is directed to microbiologists, infectious diseases clinicians, pharmacists and basic, clinical and translational researchers interested in the microbial sciences. A particular emphasis is on basic, epidemiological and pharmacological aspects of infectious diseases, including antimicrobial resistance and therapeutics.